📊 ABCL Key Takeaways
Is AbCellera Biologics Inc. (ABCL) a Good Investment?
AbCellera demonstrates strong balance sheet fundamentals with $938.1M equity and zero debt, enabling a 14.05x current ratio. However, the company burns $33.5M quarterly in operating cash flow against only $77.1M cash reserves, creating a critical 2-3 quarter runway without additional financing. Despite encouraging 160.6% revenue growth, absolute revenue of $8.3M cannot justify the operational burn rate, indicating years to profitability without significant pipeline value realization or capital raises.
AbCellera shows strong top-line momentum and an exceptionally strong balance sheet, with high liquidity, no meaningful leverage, and nearly $967M of equity supporting continued investment. However, the business remains deeply unprofitable, with very weak operating efficiency and heavily negative free cash flow, so the current fundamentals support patience rather than conviction until revenue growth translates into durable margin improvement.
AbCellera Biologics Inc. Key Strengths (ABCL)
- Zero debt with strong 938.1M stockholders equity cushion
- Excellent liquidity position (14.05x current ratio) for operational flexibility
- Robust revenue growth of 160.6% YoY demonstrates traction with customers
- Revenue grew 160.6% year over year, indicating strong commercial or milestone-driven momentum
- Balance sheet is robust with $128.51M in cash, a current ratio above 11x, and no meaningful debt burden
- Low leverage and substantial equity provide flexibility to absorb continued operating losses and fund development
ABCL Stock Risks: AbCellera Biologics Inc. Investment Risks
- Critical cash runway of only 2-3 quarters at current $33.5M quarterly burn rate
- Negative free cash flow of -$37.4M with no visible profitability timeline
- Inevitable shareholder dilution from required capital raises before achieving positive cash flow
- Operating margin of -289.0% and net margin of -194.9% show the business model is not yet generating scalable profitability
- Free cash flow of -$174.07M and negative operating cash flow indicate ongoing cash burn
- Revenue quality may be uneven if growth is driven by non-recurring collaboration or milestone payments rather than repeatable product economics
Key Metrics to Watch
- Quarterly cash burn rate trend and operating cash flow progression
- Revenue per dollar burned ratio and pathway to unit economics breakeven
- Pipeline advancement milestones and contracted revenue visibility for next 12-18 months
- Operating cash burn and free cash flow trend
- Revenue durability and operating margin improvement
AbCellera Biologics Inc. (ABCL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 14.05x current ratio provides a solid financial cushion.
ABCL Profit Margin, ROE & Profitability Analysis
ABCL vs Healthcare Sector: How AbCellera Biologics Inc. Compares
How AbCellera Biologics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is AbCellera Biologics Inc. Stock Overvalued? ABCL Valuation Analysis 2026
Based on fundamental analysis, AbCellera Biologics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
AbCellera Biologics Inc. Balance Sheet: ABCL Debt, Cash & Liquidity
ABCL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: AbCellera Biologics Inc.'s revenue has declined by 80% over the 5-year period, indicating business contraction. The most recent EPS of $-0.51 indicates the company is currently unprofitable.
ABCL Revenue Growth, EPS Growth & YoY Performance
ABCL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $4.2M | -$43.2M | $-0.14 |
| Q3 2025 | $6.5M | -$34.7M | $-0.17 |
| Q2 2025 | $7.3M | -$34.7M | $-0.12 |
| Q1 2025 | $4.2M | -$40.6M | $-0.14 |
| Q3 2024 | $6.5M | -$28.6M | $-0.10 |
| Q2 2024 | $7.3M | -$30.5M | $-0.11 |
| Q1 2024 | $10.0M | -$40.1M | $-0.14 |
| Q3 2023 | $6.6M | -$6.8M | $0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
AbCellera Biologics Inc. Dividends, Buybacks & Capital Allocation
ABCL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for AbCellera Biologics Inc. (CIK: 0001703057)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ABCL
What is the AI rating for ABCL?
AbCellera Biologics Inc. (ABCL) has a Combined AI Grade of C from Claude (C) and ChatGPT (B) with 72% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ABCL's key strengths?
Claude: Zero debt with strong 938.1M stockholders equity cushion. Excellent liquidity position (14.05x current ratio) for operational flexibility. ChatGPT: Revenue grew 160.6% year over year, indicating strong commercial or milestone-driven momentum. Balance sheet is robust with $128.51M in cash, a current ratio above 11x, and no meaningful debt burden.
What are the risks of investing in ABCL?
Claude: Critical cash runway of only 2-3 quarters at current $33.5M quarterly burn rate. Negative free cash flow of -$37.4M with no visible profitability timeline. ChatGPT: Operating margin of -289.0% and net margin of -194.9% show the business model is not yet generating scalable profitability. Free cash flow of -$174.07M and negative operating cash flow indicate ongoing cash burn.
What is ABCL's revenue and growth?
AbCellera Biologics Inc. reported revenue of $8.3M.
Does ABCL pay dividends?
AbCellera Biologics Inc. does not currently pay dividends.
Where can I find ABCL SEC filings?
Official SEC filings for AbCellera Biologics Inc. (CIK: 0001703057) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ABCL's EPS?
AbCellera Biologics Inc. has a diluted EPS of $-0.14.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is ABCL's fundamental grade?
Based on our AI fundamental analysis in June 2026, AbCellera Biologics Inc. has a C grade with 72% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is ABCL stock overvalued or undervalued?
Valuation metrics for ABCL: ROE of -4.6% (sector avg: 15%), net margin of -519.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is ABCL's AI grade for 2026?
Our dual AI analysis gives AbCellera Biologics Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ABCL's free cash flow?
AbCellera Biologics Inc.'s operating cash flow is $-33.5M, with capital expenditures of $3.8M. FCF margin is -449.2%.
How does ABCL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -519.1% (avg: 12%), ROE -4.6% (avg: 15%), current ratio 14.05 (avg: 2).